middle.news
Imricor Advances US Commercialisation with FDA Pediatric Submission for NorthStar
8:54am on Wednesday 8th of April, 2026 AEST
•
Healthcare
Read Story
Imricor Advances US Commercialisation with FDA Pediatric Submission for NorthStar
8:54am on Wednesday 8th of April, 2026 AEST
Key Points
NorthStar Mapping System submitted for FDA pediatric label expansion via Special 510(k) pathway
Submission follows January 2026 FDA clearance for adult use
Pediatric expansion targets over 250 US children’s hospitals showing inbound interest
Clearance expected within the current quarter to support US commercialization
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMRICOR MEDICAL SYSTEMS (ASX:IMR)
OPEN ARTICLE